Clofarabine (BioDeep_00000026855)

   

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol

  化学式: C10H11ClFN5O3 (303.0534)
中文名称: 克罗拉滨
  谱图信息: 最多检出来源 Homo sapiens(urine) 8.97%

分子结构信息

SMILES: C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)F)Cl)N
InChI: InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1


描述信息

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed in the U.S. and Canada as Clolar. In Europe and Australia/New Zealand the product is marketed under the name Evoltra. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Some investigations of effectiveness in cases of acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) have been carried out.
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite
C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor
D009676 - Noxae > D000963 - Antimetabolites
D000970 - Antineoplastic Agents
Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit[1].

同义名列表

68 个代谢物同义名

(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; (2R,3R,4S,5R)-5-(6-Amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arbinofuranosyl)adenine; 2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)adenine; 2-Chloro-9-(2-deoxy-2-fluoroarabinofuranosyl)adenine; 2 Chloro 2 arabino fluoro 2 deoxyadenosine; 2-Chloro-2-arabino-fluoro-2-deoxyadenosine; 2 Chloro 2 fluoroarabino 2 deoxyadenosine; 2-Chloro-2-fluoroarabino-2-deoxyadenosine; Clofarabinum; CHEMBL277800; Clofarabine; Clofarabina; CL-F-Ara-a; Clofarex; Evoltra; Clolar; CAFdA; 2-Chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine; (2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,4S,5R)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)tetrahydrofuran-3-ol; (2R,3R,4S,5R)-5-(6-Amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol 2-chloro-2''-arabino-fluoro-2''-deoxyadenosine; (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine; 2 Chloro 2' arabino fluoro 2' deoxyadenosine; 2 Chloro 2' fluoroarabino 2' deoxyadenosine; 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine; 2-chloro-2'-fluoroarabino-2'-deoxyadenosine; 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE; 2-Chloro-9-(2-Deoxy-2-Fluoro-B -D-Arabinofuranosyl)-9h-Purin-6-Amine; 2-Chloro-9-(2-deoxy-2-fluoro-b-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine; 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)adenine; 2-Cl-2'-F-araA; 6-Amino-2-chloro-9-(2'-deoxy-2'-fluoro-?-D-arabinofuranosyl)purine; 6-Amino-2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)purine; 9H-PURIN-6-AMINE, 2-CHLORO-9-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL); 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl); 9H-Purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; 9H-Purine-6-amine,2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-; C1-F-Ara-A; C10H11ClFN5O3; Cl-F-araA; Clofarabin; Clofarabine - Bio-X trade mark; Clofarabine (JAN/USAN/INN); CLOFARABINE (MART.); CLOFARABINE [EMA EPAR]; CLOFARABINE [INN]; CLOFARABINE [JAN]; CLOFARABINE [MART.]; CLOFARABINE [MI]; CLOFARABINE [ORANGE BOOK]; Clofarabine [USAN:INN:BAN]; Clofarabine [USAN]; CLOFARABINE [VANDF]; CLOFARABINE [WHO-DD]; Clofarabine, >=98% (HPLC); Clofarabine,Clolar, Evoltra; Clofarabine; Clofarex; Clolar; Evoltra; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine; 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine; Clolar (TN); L01BB06; Tox21_112182; Tox21_112182_1; WDDPHFBMKLOVOX-AYQXTPAHSA-N; 2-Chloro-9-(2'-deoxy-2'-fluoro-b-D-arabinofuranosyl)adenine



数据库引用编号

12 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome()

BioCyc()

PlantCyc()

代谢反应

个相关的代谢反应过程信息。

Reactome()

BioCyc()

WikiPathways()

Plant Reactome()

INOH()

PlantCyc()

COVID-19 Disease Map()

PathBank()

PharmGKB()

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • A Laura Nijstad, Stefan Nierkens, Caroline A Lindemans, Jaap Jan Boelens, Marc Bierings, A Birgitta Versluys, Kim C M van der Elst, Alwin D R Huitema. Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in paediatric patients. British journal of clinical pharmacology. 2021 08; 87(8):3218-3226. doi: 10.1111/bcp.14738. [PMID: 33444472]
  • Elizabeth F Krakow, Boglarka Gyurkocza, Barry E Storer, Thomas R Chauncey, Jeannine S McCune, Jerald P Radich, Michelle E Bouvier, Elihu H Estey, Rainer Storb, David G Maloney, Brenda M Sandmaier. Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. American journal of hematology. 2020 01; 95(1):48-56. doi: 10.1002/ajh.25665. [PMID: 31637757]
  • Hechuan Wang, Aksana K Jones, Christopher C Dvorak, Liusheng Huang, Paul Orchard, Vijay Ivaturi, Janel Long-Boyle. Population Pharmacokinetics of Clofarabine as Part of Pretransplantation Conditioning in Pediatric Subjects before Hematopoietic Cell Transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2019 08; 25(8):1603-1610. doi: 10.1016/j.bbmt.2019.04.017. [PMID: 31002993]
  • Natasha K A van Eijkelenburg, Mareike Rasche, Essam Ghazaly, Michael N Dworzak, Thomas Klingebiel, Claudia Rossig, Guy Leverger, Jan Stary, Eveline S J M De Bont, Dana A Chitu, Yves Bertrand, Benoit Brethon, Brigitte Strahm, Inge M van der Sluis, Gertjan J L Kaspers, Dirk Reinhardt, C Michel Zwaan. Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica. 2018 09; 103(9):1484-1492. doi: 10.3324/haematol.2017.187153. [PMID: 29773602]
  • Wanda L Salzer, Michael J Burke, Meenakshi Devidas, Si Chen, Lia Gore, Eric C Larsen, Michael Borowitz, Brent Wood, Nyla A Heerema, Andrew J Carroll, Joanne M Hilden, Mignon L Loh, Elizabeth A Raetz, Naomi J Winick, William L Carroll, Stephen P Hunger. Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. Cancer. 2018 03; 124(6):1150-1159. doi: 10.1002/cncr.31099. [PMID: 29266189]
  • Jan Moritz Middeke, Regina Herbst, Stefani Parmentier, Gesine Bug, Mathias Hänel, Gernot Stuhler, Kerstin Schäfer-Eckart, Wolf Rösler, Stefan Klein, Wolfgang Bethge, Ulrich Bitz, Bozena Büttner, Holger Knoth, Nael Alakel, Markus Schaich, Anke Morgner, Michael Kramer, Katja Sockel, Malte von Bonin, Friedrich Stölzel, Uwe Platzbecker, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2017 Sep; 23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. [PMID: 28527985]
  • Lydia L Benitez, Katherine Gharibian, David Frame, Rajen Mody, Erika Mora. Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature. Journal of pediatric hematology/oncology. 2017 08; 39(6):481-484. doi: 10.1097/mph.0000000000000845. [PMID: 28538504]
  • Arjen M Punt, Jurgen B Langenhorst, Annelies C Egas, Jaap Jan Boelens, Charlotte van Kesteren, Erik M van Maarseveen. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2017 Jun; 1055-1056(?):81-85. doi: 10.1016/j.jchromb.2017.04.025. [PMID: 28445850]
  • Martin J Barrio, Claudio Spick, Caius G Radu, Michael Lassmann, Uta Eberlein, Martin Allen-Auerbach, Christiaan Schiepers, Roger Slavik, Johannes Czernin, Ken Herrmann. Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017 03; 58(3):374-378. doi: 10.2967/jnumed.116.182394. [PMID: 27811125]
  • Mohammad Rehan Ajmal, Saima Nusrat, Parvez Alam, Nida Zaidi, Mohsin Vahid Khan, Masihuz Zaman, Yasser E Shahein, Mohamed H Mahmoud, Gamal Badr, Rizwan Hasan Khan. Interaction of anticancer drug clofarabine with human serum albumin and human α-1 acid glycoprotein. Spectroscopic and molecular docking approach. Journal of pharmaceutical and biomedical analysis. 2017 Feb; 135(?):106-115. doi: 10.1016/j.jpba.2016.12.001. [PMID: 28012306]
  • Božena Büttner, Reinhard Oertel, Johannes Schetelig, Jan Moritz Middeke, Martin Bornhäuser, Andreas Seeling, Holger Knoth. Simultaneous determination of clofarabine and cytarabine in human plasma by LC-MS/MS. Journal of pharmaceutical and biomedical analysis. 2016 Jun; 125(?):286-91. doi: 10.1016/j.jpba.2016.03.056. [PMID: 27060437]
  • Jia-Jie Luan, Yu-Shan Zhang, Xiao-Yun Liu, Ya-Qin Wang, Jian Zuo, Jian-Guo Song, Wen Zhang, Wu-San Wang. Dosing-time contributes to chronotoxicity of clofarabine in mice via means other than pharmacokinetics. The Kaohsiung journal of medical sciences. 2016 May; 32(5):227-34. doi: 10.1016/j.kjms.2016.04.001. [PMID: 27316580]
  • Woosuk Kim, Thuc M Le, Liu Wei, Soumya Poddar, Jimmy Bazzy, Xuemeng Wang, Nhu T Uong, Evan R Abt, Joseph R Capri, Wayne R Austin, Juno S Van Valkenburgh, Dalton Steele, Raymond M Gipson, Roger Slavik, Anthony E Cabebe, Thotsophon Taechariyakul, Shahriar S Yaghoubi, Jason T Lee, Saman Sadeghi, Arnon Lavie, Kym F Faull, Owen N Witte, Timothy R Donahue, Michael E Phelps, Harvey R Herschman, Ken Herrmann, Johannes Czernin, Caius G Radu. [18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity. Proceedings of the National Academy of Sciences of the United States of America. 2016 Apr; 113(15):4027-32. doi: 10.1073/pnas.1524212113. [PMID: 27035974]
  • Deniz Yılmaz Karapınar, Nihal Karadaş, Zühal Önder Siviş, Can Balkan, Kaan Kavaklı, Yeşim Aydınok. Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. Turkish journal of haematology : official journal of Turkish Society of Haematology. 2015 Sep; 32(3):263-6. doi: 10.4274/tjh.2014.0250. [PMID: 25912283]
  • Yogesh T Patel, Megan O Jacus, Nidal Boulos, Jason D Dapper, Abigail D Davis, Pradeep K Vuppala, Burgess B Freeman, Kumarasamypet M Mohankumar, Stacy L Throm, Richard J Gilbertson, Clinton F Stewart. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. Cancer chemotherapy and pharmacology. 2015 May; 75(5):897-906. doi: 10.1007/s00280-015-2713-z. [PMID: 25724157]
  • Mark A Perazella, Hassan Izzedine. New drug toxicities in the onco-nephrology world. Kidney international. 2015 May; 87(5):909-17. doi: 10.1038/ki.2015.30. [PMID: 25671763]
  • Camille R Petri, Peter H O'Donnell, Hongyuan Cao, Andrew S Artz, Wendy Stock, Amittha Wickrema, Marjie Hard, Koen van Besien. Clofarabine-associated acute kidney injury in patients undergoing hematopoietic stem cell transplant. Leukemia & lymphoma. 2014 Dec; 55(12):2866-73. doi: 10.3109/10428194.2014.897701. [PMID: 24564572]
  • Kenar D Jhaveri, Shailaja Chidella, Steven L Allen, Steven Fishbane. Clofarabine-induced kidney toxicity. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2014 Aug; 20(4):305-8. doi: 10.1177/1078155213504976. [PMID: 24081220]
  • Liusheng Huang, Patricia Lizak, Christopher C Dvorak, Francesca Aweeka, Janel Long-Boyle. Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2014 Jun; 960(?):194-9. doi: 10.1016/j.jchromb.2014.04.045. [PMID: 24820973]
  • Michael T Eadon, Heather E Wheeler, Amy L Stark, Xu Zhang, Erika L Moen, Shannon M Delaney, Hae Kyung Im, Patrick N Cunningham, Wei Zhang, M Eileen Dolan. Genetic and epigenetic variants contributing to clofarabine cytotoxicity. Human molecular genetics. 2013 Oct; 22(19):4007-20. doi: 10.1093/hmg/ddt240. [PMID: 23720496]
  • Benigno C Valdez, Guiyun Wang, David Murray, Yago Nieto, Yang Li, Jatin Shah, Francesco Turturro, Michael Wang, Donna M Weber, Richard E Champlin, Muzaffar H Qazilbash, Borje S Andersson. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Experimental hematology. 2013 Aug; 41(8):719-30. doi: 10.1016/j.exphem.2013.04.009. [PMID: 23648290]
  • Koen van Besien, Wendy Stock, Elizabeth Rich, Olatoyosi Odenike, Lucy A Godley, Peter H O'Donnell, Justin Kline, Vu Nguyen, Paula Del Cerro, Richard A Larson, Andrew S Artz. Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2012 Jun; 18(6):913-21. doi: 10.1016/j.bbmt.2011.10.041. [PMID: 22079470]
  • David Claxton, Harry P Erba, Stefan Faderl, Martha Arellano, Roger M Lyons, Tibor Kovacsovics, Janice Gabrilove, Dirk Huebner, Pritesh J Gandhi, Hagop Kantarjian. Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leukemia & lymphoma. 2012 Mar; 53(3):435-40. doi: 10.3109/10428194.2011.616960. [PMID: 21877883]
  • Thomas Mueller, Wieland Voigt. Fermented wheat germ extract--nutritional supplement or anticancer drug?. Nutrition journal. 2011 Sep; 10(?):89. doi: 10.1186/1475-2891-10-89. [PMID: 21892933]
  • Polly E Kintzel, James A Visser, Alan D Campbell. Clofarabine-associated acute kidney injury and proteinuria. Pharmacotherapy. 2011 Sep; 31(9):923. doi: 10.1592/phco.31.9.923. [PMID: 21923594]
  • Janel Long-Boyle, Jiayin Huang, Nancy Rydholm, Angela Smith, Paul Orchard, Jakub Tolar, Pamala Jacobson. Pharmacokinetics of clofarabine in patients with high-risk inherited metabolic disorders undergoing brain-sparing hematopoietic cell transplantation. Journal of clinical pharmacology. 2011 May; 51(5):679-86. doi: 10.1177/0091270010372519. [PMID: 20525919]
  • Peter L Bonate, Casey C Cunningham, Paul Gaynon, Sima Jeha, Richard Kadota, Gilbert N Lam, Bassem Razzouk, Michael Rytting, Peter Steinherz, Steve Weitman. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer chemotherapy and pharmacology. 2011 Apr; 67(4):875-90. doi: 10.1007/s00280-010-1376-z. [PMID: 20582417]
  • Helene Sudour, Antoine Kimmoun, Audrey Contet, Laurence Clement, Alexandra Salmon, Claudine Schmitt, Pascal Chastagner. Successful management with clofarabine for refractory leukaemia in a young adult with chronic renal failure. American journal of hematology. 2011 Mar; 86(3):321-3. doi: 10.1002/ajh.21965. [PMID: 21328440]
  • Peter G Steinherz, Neerav Shukla, Rachel Kobos, Sheron Latcha. Effect of hemodialysis on the plasma levels of clofarabine. Pediatric blood & cancer. 2010 Jul; 55(1):196-8. doi: 10.1002/pbc.22458. [PMID: 20232428]
  • Antoinette D Ajavon, Peter L Bonate, David R Taft. Renal excretion of clofarabine: assessment of dose-linearity and role of renal transport systems on drug excretion. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2010 Jun; 40(3):209-16. doi: 10.1016/j.ejps.2010.03.014. [PMID: 20347037]
  • M G Martin, G L Uy, E Procknow, K Stockerl-Goldstein, A Cashen, P Westervelt, C N Abboud, K Augustin, J Luo, J F DiPersio, R Vij. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone marrow transplantation. 2009 Jul; 44(1):13-7. doi: 10.1038/bmt.2008.423. [PMID: 19139740]
  • Adam N Elwi, Vijaya L Damaraju, Michelle L Kuzma, Delores A Mowles, Stephen A Baldwin, James D Young, Michael B Sawyer, Carol E Cass. Transepithelial fluxes of adenosine and 2'-deoxyadenosine across human renal proximal tubule cells: roles of nucleoside transporters hENT1, hENT2, and hCNT3. American journal of physiology. Renal physiology. 2009 Jun; 296(6):F1439-51. doi: 10.1152/ajprenal.90411.2008. [PMID: 19297449]
  • Bradley A McGregor, Alexander W Brown, Michael B Osswald, Michael R Savona. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. American journal of hematology. 2009 Apr; 84(4):228-30. doi: 10.1002/ajh.21365. [PMID: 19260120]
  • Luke H Stockwin, Sherry X Yu, Howard Stotler, Melinda G Hollingshead, Dianne L Newton. ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC cancer. 2009 Feb; 9(?):63. doi: 10.1186/1471-2407-9-63. [PMID: 19232100]
  • Yunsheng Hsieh, Christine J G Duncan, Suining Lee, Ming Liu. Comparison of fast liquid chromatography/tandem mass spectrometric methods for simultaneous determination of cladribine and clofarabine in mouse plasma. Journal of pharmaceutical and biomedical analysis. 2007 Jun; 44(2):492-7. doi: 10.1016/j.jpba.2007.02.007. [PMID: 17368998]
  • Anna Fyrberg, Freidoun Albertioni, Kourosh Lotfi. Cell cycle effect on the activity of deoxynucleoside analogue metabolising enzymes. Biochemical and biophysical research communications. 2007 Jun; 357(4):847-53. doi: 10.1016/j.bbrc.2007.03.176. [PMID: 17459340]
  • Alex H Beesley, Misty-Lee Palmer, Jette Ford, Renae E Weller, Aaron J Cummings, Joseph R Freitas, Martin J Firth, Kanchana U Perera, Nicholas H de Klerk, Ursula R Kees. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. British journal of haematology. 2007 Apr; 137(2):109-16. doi: 10.1111/j.1365-2141.2007.06527.x. [PMID: 17391490]
  • Karen M King, Vijaya L Damaraju, Mark F Vickers, Sylvia Y Yao, Thach Lang, Tracey E Tackaberry, Delores A Mowles, Amy M L Ng, James D Young, Carol E Cass. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Molecular pharmacology. 2006 Jan; 69(1):346-53. doi: 10.1124/mol.105.015768. [PMID: 16234483]
  • Tadeusz Robak, Ewa Lech-Maranda, Anna Korycka, Ewa Robak. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Current medicinal chemistry. 2006; 13(26):3165-89. doi: 10.2174/092986706778742918. [PMID: 17168705]
  • Stacey L Berg, Peter L Bonate, Jed G Nuchtern, Robert Dauser, Leticia McGuffey, Bruce Bernacky, Susan M Blaney. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Aug; 11(16):5981-3. doi: 10.1158/1078-0432.ccr-05-0261. [PMID: 16115942]
  • Peter L Bonate, Larry Arthaud, John Stuhler, Phyllis Yerino, Randall J Press, James Q Rose. The distribution, metabolism, and elimination of clofarabine in rats. Drug metabolism and disposition: the biological fate of chemicals. 2005 Jun; 33(6):739-48. doi: 10.1124/dmd.104.002592. [PMID: 15743978]
  • Stefan Faderl, Varsha Gandhi, Susan O'Brien, Peter Bonate, Jorge Cortes, Elihu Estey, Miloslav Beran, William Wierda, Guillermo Garcia-Manero, Alessandra Ferrajoli, Zeev Estrov, Francis J Giles, Min Du, Monica Kwari, Michael Keating, William Plunkett, Hagop Kantarjian. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb; 105(3):940-7. doi: 10.1182/blood-2004-05-1933. [PMID: 15486072]
  • Peter L Bonate, Adam Craig, Paul Gaynon, Varsha Gandhi, Sima Jeha, Richard Kadota, Gilbert N Lam, William Plunkett, Bassem Razzouk, Michael Rytting, Peter Steinherz, Steve Weitman. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. Journal of clinical pharmacology. 2004 Nov; 44(11):1309-22. doi: 10.1177/0091270004269236. [PMID: 15496649]
  • Todd Cooper, Hagop Kantarjian, William Plunkett, Varsha Gandhi. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides, nucleotides & nucleic acids. 2004 Oct; 23(8-9):1417-23. doi: 10.1081/ncn-200027650. [PMID: 15571270]
  • Varsha Gandhi, Hagop Kantarjian, Stefan Faderl, Peter Bonate, Min Du, Mary Ayres, Mary Beth Rios, Michael J Keating, William Plunkett. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Dec; 9(17):6335-42. doi: NULL. [PMID: 14695132]
  • M Bayés, X Rabasseda, J R Prous. Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology. 2003 Jul; 25(6):483-506. doi: . [PMID: 12949633]
  • Hagop M Kantarjian, Varsha Gandhi, Peter Kozuch, Stefan Faderl, Francis Giles, Jorge Cortes, Susan O'Brien, Nuhad Ibrahim, Fadlo Khuri, Min Du, Mary Beth Rios, Sima Jeha, Peter McLaughlin, William Plunkett, Michael Keating. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Mar; 21(6):1167-73. doi: 10.1200/jco.2003.04.031. [PMID: 12637486]
  • S Lindemalm, J Liliemark, B S Larsson, F Albertioni. Distribution of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, fludarabine and cytarabine in mice: a whole-body autoradiography study. Medical oncology (Northwood, London, England). 1999 Dec; 16(4):239-44. doi: 10.1007/bf02785869. [PMID: 10618686]
  • S Lindemalm, F Albertioni, J Liliemark. Stability and analysis of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine and 2-chloroadenine in human blood plasma. Anti-cancer drugs. 1997 Jun; 8(5):445-53. doi: 10.1097/00001813-199706000-00005. [PMID: 9215606]
  • M Qian, X Wang, K Shanmuganathan, C K Chu, J M Gallo. Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine in rats. Cancer chemotherapy and pharmacology. 1994; 33(6):484-8. doi: 10.1007/bf00686505. [PMID: 8137458]
  • D A Carson, D B Wasson, L M Esparza, C J Carrera, T J Kipps, H B Cottam. Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine. Proceedings of the National Academy of Sciences of the United States of America. 1992 Apr; 89(7):2970-4. doi: 10.1073/pnas.89.7.2970. [PMID: 1348362]